North America Defibrillator Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Implantable Cardioverter Defibrillator and External) and End User (Hospitals and Clinics, Prehospital Care, Public Access, Home Care Settings, and Alte

North America Defibrillator Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Implantable Cardioverter Defibrillator and External) and End User (Hospitals and Clinics, Prehospital Care, Public Access, Home Care Settings, and Alternate Care Facilities)

The defibrillator market in North America is expected to grow from US$ 4,575.28 million in 2021 to US$ 6,597.93 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2021 to 2028. The awareness regarding cardiopulmonary resuscitation (CPR) and automated external defibrillators (AED) is high in western countries. ~700,000 cases of out-of-hospital cardiac arrest (OHCA) occurred in the US in 2019, with a significant percentage of these occurring at home and in public settings. A study titled “The Global Survival Rate Among Adult Out-Of-Hospital Cardiac Arrest Patients Who Received Cardiopulmonary Resuscitation: A Systematic Review and Meta-Analysis,” published in 2020, assessed the survival rates of OHCA patients, who received CPR from a bystander or emergency medical services, and were living in a particular region. The study reported a significant rise in the survival rates from the OHCA in the past years, and the rates are greater among patients who received CPR or AED and were living in western countries. A study by the American Heart Association found that the median average for survival from a cardiac arrest with near-immediate bystander CPR and use of a public access defibrillator was ~40%. Online and offline training programs by organizations such as the WHO, the US FDA, regional health centers, and local bodies have increased significantly. Various states in the US have enacted legislation to encourage the use of defibrillators and the availability of AEDs; they have also made provisions for educating and training people for the use and maintenance of AEDs. Further, the health authorities are creating a registry of locations where AEDs are present for public access. OHCA of a famous football player during an international match has been one of the recent incidents that boosted the awareness regarding such incidences and adoption of defibrillators at various locations; the use of defibrillators helped paramedic teams save the player’s life. Therefore, data available from the positive outcome of the use of AED and CPR on OHCA in public settings, along with the rising awareness, training, and legislation, boosts the defibrillator market growth.

In North America, the US was severely impacted by the emergence of the COVID-19 pandemic. The country has had the highest number of COVID-19 patients with over 68 million reported cases and more than 856,000 deaths as per data given by the US Department of Health & Human Services and CDC as of January 19, 2022.The US is going through another surge in COVID-19 cases due to the omicron variant of SARS-CoV-2, which is expected to peak by January-end, 2022. Mexico is going through its biggest COVID-19 wave and has been registering a massive surge in COVID-19 cases. Similarly, Canada has gone through a recent wave of COVID-19 with the total number of cases rising to over ~2.84 million and 32,000 deaths, as of January 20th, 2022. As the hospital admissions and pressure on the healthcare infrastructure rose, the demand for defibrillators and other medical devices increased owing to their importance in in-hospital resuscitation and in-home settings with implantable cardioverter?defibrillator. Initial assessments showed fast, abnormal heart rates as a symptom experienced by many COVID-19 patients, and therefore, various recommendations and bulletins were issued by the CDC and the American College of Cardiology warning patients about the potential risk for cardiac patients and encouraging the use of automated external defibrillators along with various other precautions. As people with heart conditions were at the highest risk of contracting SARS-CoV-2, the demand for defibrillators in hospitals peaked, which were needed to treat cardiac arrests in critically ill patients. Studies conducted by various authorities showed a rise in the importance of defibrillators in hospitals and an increase in the usage of defibrillators in other settings. Organizations such as the World Health Organization (WHO), CDC, and the American College of Cardiology emphasized the presence of defibrillators in hospitals as an essential tool for combating the disease. The International Liaison Committee on Resuscitation or ILCOR also updated their guidelines through focused defibrillation training to avoid compromising the care of the patient experiencing tachyarrhythmia arrests, which also protected the caregiver from exposure to the virus. A 2020 study titled “Implantable Cardioverter?Defibrillator Shocks During COVID?19 Outbreak” by Adabag et.al., used the Medtronic Carelink database during 2019-2020 to determine the incidence of implantable defibrillator shock episodes among patients residing in New York, New Orleans, and Boston. The study found a significant increase in defibrillator shock episodes during the COVID-19 pandemic compared to 2019. Another study published in 2021 titled “The Role of the Automated Implantable Cardioverter Defibrillator (AICD) for Secondary Prevention in the COVID-19 Era,” presented a case of COVID-19 in a New York City Hospital who rapidly developed sudden cardiac arrest after presenting to the emergency room. The study concluded by emphasizing the use of automated implantable cardioverter defibrillator (AICD) with subclinical cardiac injury in COVID-19 patients post-recovery showing an upward trend. The study recommended the use of AICD as a secondary preventive measure to prevent recurrence of SCA and sudden cardiac deaths. Various studies, rise in the number of COVID-19 cases, and emphasis laid down on the use of defibrillators as a preventive instrument in preventing cardiac arrests by various governmental and nongovernmental organizations showcased a positive impact on the defibrillator market with the application of defibrillators rising in hospitals and nonhospital.

Based on product, the market is bifurcated into implantable cardioverter defibrillator (ICD) and external. In 2020, the implantable cardioverter defibrillator segment held a larger share in the North America defibrillator market. An implantable cardioverter-defibrillator (ICD) is a small battery-powered device that detects and stops irregular heartbeats (arrhythmias) in the chest. An ICD continuously monitors the heartbeat and, if necessary, administers electric shocks to restore normal heart rhythm. ICDs are used to avoid sudden death in patients undergoing fibrillation or persistent ventricular tachycardia. It can help avert cardiac arrest in patients who are at high risk of life-threatening arrhythmias. Next-generation ICDs can also function as a pacemaker. If the heart rate slows, the pacemaker feature can stimulate the heart to beat. The increased demand for ICDs for patients with nonischemic cardiomyopathy has improved survival rates and reduced mortality risk, which is projected to provide opportunities for ICD manufacturers, propelling the market growth. The ICD segment is further bifurcated into transvenous ICD and subcutaneous ICD.

The overall North America defibrillator market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast for the North America defibrillator market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain more analytical insights into the topic. The participants involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the North America defibrillator market. Abbott; Biotronik, Inc; Boston Scientific Corporation; Koninklijke Philips N.V.; Medtronic; Nihon Kohden Corporation; Shenzhen Mindray Biomedical Electronics Co., Ltd; and ZOLL MEDICAL CORPORATION are among the key players operating in the North America defibrillator market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Defibrillator Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America Defibrillator Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the Defibrillator Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution